Alkermes plc

Alkermes plc

41.22
EUR
+0.03
(+0.07%)
6.01BMarket Cap
Feb 17Next Earn

Alkermes plc Documents

Q3 FY2025 · Press release

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 · November 12, 2025 · 3 pages

Read Alkermes plc's results firsthand

Preview the first 2 pages of this press release
Create a free account to start reading

Full documents are included with Professional

Q3 FY2025 documents